Mechanistic network models in safety and toxicity evaluation of nutraceuticals

Nutraceuticals: Efficacy, Safety and Toxicity

Volumn , Issue , 2016, Pages 287-304

  Gonzalez Suarez, Ignacio ^a   Martin, Florian ^a   Hoeng, Julia ^a   Peitsch, Manuel C ^a  

^a PHILIP MORRIS PRODUCTS S A   (Switzerland)

Author keywords

Astaxanthin; Biological networks; Epigallocatechin gallate; High content screening; Quercetin; Resveratrol; Systems toxicology

Indexed keywords

EID: 84967215055     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-802147-7.00022-X     Document Type: Chapter

References (88)

1. Ahmad A., Ginnebaugh K.R., Li Y., et al. Molecular targets of naturopathy in cancer research: bridge to modern medicine. Nutrients 2015, 7:321-334.
2. Andersen M.E., Krewski D. Toxicity testing in the 21st century: bringing the vision to life. Toxicol. Sci. 2009, 107:324-330.
3. Anderson N., Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006, 580:5533-5540.
4. Ansari S., Binder J., Boue S., et al. On crowd-verification of biological networks. Bioinform. Biol. Insights 2013, 7:307-325.
5. AoE T.N.a.A. Toxicity Testing in the 21st Century: A Vision and a Strategy 2007, National Academy Press, Washington, DC.
6. Aragon F., Perdigon G., de Moreno de LeBlanc A. Modification in the diet can induce beneficial effects against breast cancer. World J. Clin. Oncol. 2014, 5:455-464.
7. Bhattacharya S., Zhang Q., Carmichael P.L., et al. Toxicity testing in the 21 century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PLoS One 2011, 6:e20887.
8. Boesch-Saadatmandi C., Loboda A., Wagner A.E., et al. Effect of quercetin and its metabolites isorhamnetin and quercetin-3-glucuronide on inflammatory gene expression: role of miR-155. J. Nutr. Biochem. 2011, 22:293-299.
9. Boots A.W., Kubben N., Haenen G.R., et al. Oxidized quercetin reacts with thiols rather than with ascorbate: implication for quercetin supplementation. Biochem. Biophys. Res. Commun. 2003, 308:560-565.
10. Bradamante S., Barenghi L., Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev. 2004, 22:169-188.
11. Byrne M.M., Murphy R.T., Ryan A.W. Epigenetic modulation in the treatment of atherosclerotic disease. Front. Genet. 2014, 5:364.
12. Catlett N.L., Bargnesi A.J., Ungerer S., et al. Reverse causal reasoning: applying qualitative causal knowledge to the interpretation of high-throughput data. BMC Bioinformatics 2013, 14:340.
13. Chin Y.T., Hsieh M.T., Yang S.H., et al. Anti-proliferative and gene expression actions of resveratrol in breast cancer cells in vitro. Oncotarget 2014, 5:12891-12907.
14. Choi K.C., Jung M.G., Lee Y.H., et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 2009, 69:583-592.
15. Collins F.S., Gray G.M., Bucher J.R. Toxicology. Transforming environmental health protection. Science 2008, 319(5865):906-907.
16. Collins Q.F., Liu H.Y., Pi J., et al. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase. J. Biol. Chem. 2007, 282:30143-30149.
17. Cottart C.H., Nivet-Antoine V., Laguillier-Morizot C., et al. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54:7-16.
18. De Leon H., Boue S., Schlage W.K., et al. A vascular biology network model focused on inflammatory processes to investigate atherogenesis and plaque instability. J. Transl. Med. 2014, 12:185.
19. Donato M.T., Gomez-Lechon M.J. Drug-induced liver steatosis and phospholipidosis: cell-based assays for early screening of drug candidates. Curr. Drug Metab. 2012, 13:1160-1173.
20. Doring F., Rimbach G. Nutri-informatics: a new kid on the block?. Genes Nutr. 2014, 9:394.
21. Enns J.E., Yeganeh A., Zarychanski R., et al. The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis. BMC Cardiovasc. Disord. 2014, 14:70.
22. EPA Next Generation Risk Assessment: Incorporation of Recent Advances in Molecular, Computational, and Systems Biology (External Review Draft) 2013, U. S. E. P. Agency, Washington, DC, EPA/600/R-13/214A. Available from: http://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=259936#Download (accessed 28.04.14).
23. Espin J.C., Garcia-Conesa M.T., Tomas-Barberan F.A. Nutraceuticals: facts and fiction. Phytochemistry 2007, 68:2986-3008.
24. EU Commission, 2009. Alternative Testing Strategies-Progress Report 2009: Replacing, Reducing and Refining Use of Animals in Research-Genomics & Biotechnology for Health. Office for Official Publications of the European Communities, Luxembourg.
25. FDA, 1994. Dietary Supplement Health and Education Act of 1994. U. F. a. D. Administration.
26. FDA, 2009. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation.
27. FDA, 2014. GRAS notices. Available from:. http://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices.
28. Fremont L. Biological effects of resveratrol. Life Sci. 2000, 66(8):663-673.
29. Fu Y., Zheng S., Lu S.C., Chen A. Epigallocatechin-3-gallate inhibits growth of activated hepatic stellate cells by enhancing the capacity of glutathione synthesis. Mol. Pharmacol. 2008, 73:1465-1473.
30. Gebel S., Lichtner R.B., Frushour B., et al. Construction of a computable network model for DNA damage, autophagy, cell death, and senescence. Bioinform. Biol. Insights 2013, 7:97-117.
31. Gonzalez-Suarez I., Sewer A., Walker P., et al. Systems biology approach for evaluating the biological impact of environmental toxicants in vitro. Chem. Res. Toxicol. 2014, 27:367-376.
32. Guo Y., Xiao P., Lei S., et al. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim. Biophys. Sin. (Shanghai) 2008, 40:426-436.
33. Gylling H., Plat J., Turley S., et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014, 232:346-360.
34. Hartung T., van Vliet E., Jaworska J., et al. Systems toxicology. ALTEX 2012, 29:119-128.
35. Harwood M., Danielewska-Nikiel B., Borzelleca J.F., et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol. 2007, 45:2179-2205.
36. Hoeng J., Deehan R., Pratt D., et al. A network-based approach to quantifying the impact of biologically active substances. Drug Discov. Today 2012, 17:413-418.
37. Hoeng J., Talikka M., Martin F., et al. Toxicopanomics: applications of genomics, transcriptomics, proteomics and lipidomics in predictive mechanistic toxicology. Hayes' Principles and Methods of Toxicology 2014, CRC Press, Boca Raton, FL, pp. 295-332.
38. Ideker T., Dutkowski J., Hood L. Boosting signal-to-noise in complex biology: prior knowledge is power. Cell 2011, 144:860-863.
39. Isbrucker R.A., Bausch J., Edwards J.A., et al. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 1: genotoxicity. Food Chem. Toxicol. 2006, 44:626-635.
40. Isbrucker R.A., Edwards J.A., Wolz E., et al. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem. Toxicol. 2006, 44:636-650.
41. Jang M., Cai L., Udeani G.O., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
42. Khatri P., Sirota M., Butte A.J. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput. Biol. 2012, 8:e1002375.
43. Khurana S., Venkataraman K., Hollingsworth A., et al. Polyphenols: benefits to the cardiovascular system in health and in aging. Nutrients 2013, 5:3779-3827.
44. Krewski D., Westphal M., Al-Zoughool M., Croteau M.C., Andersen M.E. New directions in toxicity testing. Annu. Rev. Public Health 2011, 32:161-178.
45. Lambert J.D., Kennett M.J., Sang S., et al. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem. Toxicol. 2010, 48:409-416.
46. Lambert J.D., Sang S., Hong J., et al. Anticancer and anti-inflammatory effects of cysteine metabolites of the green tea polyphenol, (-)-epigallocatechin-3-gallate. J. Agric. Food Chem. 2010, 58:10016-10019.
47. Lee W.J., Shim J.Y., Zhu B.T. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol. 2005, 68:1018-1030.
48. Lemasters J.J., Theruvath T.P., Zhong Z., et al. Mitochondrial calcium and the permeability transition in cell death. Biochim. Biophys. Acta 2009, 1787:1395-1401.
49. Lowndes N.F., Toh G.W. DNA repair: the importance of phosphorylating histone H2AX. Curr. Biol. 2005, 15:R99-R102.
50. Ma T., Tan M., Yu J., Tan L. Resveratrol as a therapeutic agent for Alzheimer's disease. Biomed. Res. Int. 2014, 2014:350516.
51. Mandair D., Rossi R.E., Pericleous M., et al. Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutr. Metab. (Lond.) 2014, 11:30.
52. Martin F., Thomson T.M., Sewer A., et al. Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks. BMC Syst. Biol. 2012, 6:54.
53. Martin F., Sewer A., Talikka M., et al. Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models. BMC Bioinformatics 2014, 15:238.
54. Matsuo M., Sasaki N., Saga K., et al. Cytotoxicity of flavonoids toward cultured normal human cells. Biol. Pharm. Bull. 2005, 28:253-259.
55. Mecocci P., Tinarelli C., Schulz R.J., et al. Nutraceuticals in cognitive impairment and Alzheimer's disease. Front. Pharmacol. 2014, 5:147.
56. Meyer P., Alexopoulos L.G., Bonk T., et al. Verification of systems biology research in the age of collaborative competition. Nat. Biotechnol. 2011, 29:811-815.
57. Nagendraprabhu P., Sudhandiran G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Invest. New Drugs 2011, 29:207-224.
58. Naito Y., Uchiyama K., Aoi W., et al. Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. Biofactors 2004, 20:49-59.
59. Park J.S., Schlage W.K., Frushour B., et al. Construction of a computable network model of tissue repair and angiogenesis in the lung. J. Clin. Toxicol. 2013, S12:002.
60. Perez-Vizcaino F., Duarte J., Andriantsitohaina R. Endothelial function and cardiovascular disease: effects of quercetin and wine polyphenols. Free Radic. Res. 2006, 40:1054-1065.
61. Pervaiz S., Holme A.L. Resveratrol: its biologic targets and functional activity. Antioxid. Redox Signal. 2009, 11:2851-2897.
62. Russell W.M.S., Burch R.L. The Principles of Humane Experimental Technique 1959, Methuen, London.
63. Sadowska-Bartosz I., Bartosz G. Effects of antioxidants supplementation on aging and longevity. BioMed Res. Int. 2014, 2014:1-17.
64. Sahu S.C., Washington M.C. Effects of antioxidants on quercetin-induced nuclear DNA damage and lipid peroxidation. Cancer Lett. 1991, 60:259-264.
65. Sahu S.C., Washington M.C. Quercetin-induced lipid peroxidation and DNA damage in isolated rat-liver nuclei. Cancer Lett. 1991, 58:75-79.
66. Schlage W.K., Westra J.W., Gebel S., et al. A computable cellular stress network model for non-diseased pulmonary and cardiovascular tissue. BMC Syst. Biol. 2011, 5:168.
67. Schwanhausser B., Busse D., Li N., et al. Global quantification of mammalian gene expression control. Nature 2011, 473:337-342.
68. Selventa, 2013. OpenBEL. Available from:. http://www.openbel.org.
69. Shankavaram U.T., Reinhold W.C., Nishizuka S., et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol. Cancer Ther. 2007, 6:820-832.
70. Shen H., Kuo C.C., Chou J., et al. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J. 2009, 23:1958-1968.
71. Shukla S.J., Huang R., Austin C.P., Xia M. The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform. Drug Discov. Today 2010, 15(23-24):997-1007.
72. Simmons S.O., Fan C.Y., Ramabhadran R. Cellular stress response pathway system as a sentinel ensemble in toxicological screening. Toxicol. Sci. 2009, 111:202-225.
73. Stewart J.S., Lignell A., Pettersson A., et al. Safety assessment of astaxanthin-rich microalgae biomass: acute and subchronic toxicity studies in rats. Food Chem. Toxicol. 2008, 46:3030-3036.
74. Sturla S.J., Boobis A.R., FitzGerald R.E., et al. Systems toxicology: from basic research to risk assessment. Chem. Res. Toxicol. 2014, 27:314-329.
75. Subramanian A., Tamayo P., Mootha V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15545-15550.
76. Suzuki K., Yahara S., Hashimoto F., Uyeda M. Inhibitory activities of (-)-epigallocatechin-3-O-gallate against topoisomerases I and II. Biol. Pharm. Bull. 2001, 24:1088-1090.
77. Tago Y., Fujii T., Wada J., et al. Genotoxicity and subacute toxicity studies of a new astaxanthin-containing Phaffia rhodozyma extract. J. Toxicol. Sci. 2014, 39:373-382.
78. Thermo-Scientific, 2012. Thermo Scientific CellInsight NXT High Content Screening Platform Brochure. https://static.thermoscientific.com/images/D21328~.pdf.
79. Thomson T.M., Sewer A., Martin F., et al. Quantitative assessment of biological impact using transcriptomic data and mechanistic network models. Toxicol. Appl. Pharmacol. 2013, 272:863-878.
80. Tice R.R., Austin C.P., Kavlock R.J., et al. Improving the human hazard characterization of chemicals: a Tox21 update. Environ. Health Perspect. 2013, 121:756-765.
81. Walle T., Vincent T.S., Walle U.K. Evidence of covalent binding of the dietary flavonoid quercetin to DNA and protein in human intestinal and hepatic cells. Biochem. Pharmacol. 2003, 65:1603-1610.
82. Wang C.T., Chang H.H., Hsiao C.H., et al. The effects of green tea (-)-epigallocatechin-3-gallate on reactive oxygen species in 3T3-L1 preadipocytes and adipocytes depend on the glutathione and 67kDa laminin receptor pathways. Mol. Nutr. Food Res. 2009, 53:349-360.
83. Westra J.W., Schlage W.K., Frushour B.P., et al. Construction of a computable cell proliferation network focused on non-diseased lung cells. BMC Syst. Biol. 2011, 5:105.
84. Westra J.W., Schlage W.K., Hengstermann A., et al. A modular cell-type focused inflammatory process network model for non-diseased pulmonary tissue. Bioinform. Biol. Insights 2013, 7:167-192.
85. WHO, 2015. Healthy Diet: Fact sheet no 394. World Health Organization, Geneva, Switzerland. Available from: [accessed 12.02.2015]. http://www.who.int/mediacentre/factsheets/fs394/en/.
86. Wisdom R., Johnson R.S., Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999, 18:188-197.
87. Yuan J.P., Peng J., Yin K., Wang J.H. Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae. Mol. Nutr. Food Res. 2011, 55:150-165.
88. Zhang Y., Yi B., Ma J., et al. Quercetin promotes neuronal and behavioral recovery by suppressing inflammatory response and apoptosis in a rat model of intracerebral hemorrhage. Neurochem. Res. 2015, 40:195-203.